Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
When one major player faces regulatory hurdles, it often creates opportunities for competitors. The European rejection of a leading gene therapy for Duchenne muscular dystrophy has opened the door for rival companies with alternative approaches to capture market share in this high-value rare disease market.
What You Need to Know
This group focuses on biopharmaceutical companies developing treatments for rare genetic muscle disorders. These firms use various approaches from gene therapies to different molecular treatments. The regulatory setback highlights the high standards required for approval, making successful alternatives potentially more valuable.
Why These Stocks
These companies were handpicked by professional analysts as potential beneficiaries of the competitive shift in the Duchenne treatment landscape. Each represents a different therapeutic approach that could now be better positioned to attract investment and capture market opportunities following the regulatory decision.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+133.03%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 133.03% over the next year.
Stocks Rated Buy by Analysts
15 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Market Door Just Opened
A major competitor's regulatory setback has created a rare opportunity for rivals to step into a valuable rare disease market. When one player stumbles, others often surge ahead.
Gene Therapy Gold Rush
The biotech sector is racing to develop breakthrough treatments for genetic disorders. These companies represent different approaches that could capture significant market share in this high-growth space.
Rare Disease, Big Rewards
Successful treatments for rare genetic conditions often command premium pricing and strong market positions. These catalyst-driven opportunities can deliver substantial returns for early investors.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.